HSCI co-director David Scadden is part of a multi-institutional, cross-disciplinary team that has been awarded a $14.6 million grant from the National Institutes of Health. The team is using gene and cell therapy approaches to develop a potential cure for HIV.

The researchers will combine gene editing against HIV with technologies for safer and more effective blood stem cell transplants. Such transplants, also known as bone marrow transplants, are currently used for severe blood cancers. They renew a patient’s immune system, which can be damaged by cancer therapies, by...

HSCI researchers identify mechanism that links metabolism and cell signaling

Cancer immunologists and biological engineers at Harvard unite to fight therapy-resistant cancers

A new NIH-funded Immuno-Engineering to Improve Immunotherapy (i3) Center at Harvard...